TMDX — TransMedics Group, Inc.

Summary of TMDX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $160.8 million, up 32% year-over-year and 12% sequentially.
• U.S. Transplant Revenue: $155 million, reflecting an 11% sequential increase.
• Operating Profit: $21.3 million (13.2% of revenue).
• Full Year 2025 Revenue: $605.5 million, a 37% increase from 2024.
• Full Year Operating Profit: $108.6 million (18% of revenue).
• Net Income for Q4: $105 million, boosted by an $83.8 million tax benefit.
• Cash Position: $488.4 million at year-end, up $22 million from Q3 2025.
• Earnings Per Share: $5.60 for the full year and $3.08 for Q4.

2. Strategic Updates and Business Highlights

• Operational Performance: Strong growth driven by increased OCS (Organ Care System) adoption, particularly in liver and heart transplants.
• Transplant Logistics: Revenue from transplant logistics services reached $28.6 million in Q4, a 32% increase year-over-year.
• OCS Transplant Volumes: 5,139 OCS transplants in the U.S. for 2025, up from 3,735 in 2024, representing 26% of total U.S. transplants.
• Clinical Programs: Focus on ENHANCE Heart and DENOVO Lung programs to drive adoption and expand market share.
• International Expansion: Plans to launch NOP model in Europe, with initial efforts in Italy.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected between $727 million and $757 million, representing 20% to 25% growth over 2025.
• Gross Margin Expectations: Anticipated to remain around 60% long-term, with potential near-term volatility due to international expansion and increased investments.
• Operating Margins: Expected to contract by approximately 250 basis points in 2026 due to increased investments in clinical programs and infrastructure.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Challenges in executing Part B of the ENHANCE trial due to competitors' reluctance to randomize against OCS technology.
• Seasonality Effects: Anticipated Q3 slowdowns in U.S. transplant activities may impact performance.
• Operational Challenges: Building out logistics infrastructure in Europe could moderate initial growth.
• Lung and Heart Segment Performance: Lower-than-expected contributions from heart and lung transplants in Q4, attributed to trial delays and market dynamics.

5. Notable Q&A Insights

• Guidance Philosophy: Management expressed confidence in their guidance, factoring in both opportunities and uncertainties.
• OCS Liver Adoption: Upcoming registry publications expected to provide significant data supporting OCS liver adoption amidst emerging competition.
• NOP Connect 2.0: Early results show operational efficiencies, with most cases now utilizing the platform.
• Heart Trial Feedback: Positive initial feedback from transplant surgeons on the heart clinical trial, though specific results are pending.
• OPO Environment: Management supports proposed changes to the organ procurement system, viewing it as an opportunity for TransMedics to enhance its role in the transplant ecosystem.

Overall, TransMedics demonstrated strong financial performance in Q4 2025, with significant growth in revenue and operating profit, while outlining ambitious plans for 2026 amidst some competitive and operational challenges.